Rituximab improved dexamethasone response rates in immune thrombocytopenia Healio Researchers randomly assigned 71 patients to dexamethasone 40 mg/day for 4 days, and 62 patients were assigned this dexamethasone regimen plus rituximab (Rituxan, Genentech/Biogen Idec) 375 mg/m2 weekly for 4 weeks. The study protocol allowed ... |
